avacincaptad pegol

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy, Age-Related Macular Degeneration

Trial Timeline

Jul 8, 2025 → Jun 30, 2027

NCT ID

NCT06970665

About avacincaptad pegol

avacincaptad pegol is a approved stage product being developed by Astellas Pharma for Geographic Atrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06970665. Target conditions include Geographic Atrophy, Age-Related Macular Degeneration.

What happened to similar drugs?

0 of 11 similar drugs in Geographic Atrophy were approved

Approved (0) Terminated (3) Active (8)

🔄avacincaptad pegolAstellas PharmaPhase 3

🔄Avacincaptad Pegol + ShamAstellas PharmaPhase 3

❌LampalizumabRochePhase 3

🔄Tinlarebant + PlaceboBelite BioPhase 3

🔄APL-2 + APL-2Apellis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06970665	Approved	Recruiting	Jul 8, 2025	Jun 30, 2027	Geographic Atrophy
NCT05536297	Phase 3	Completed	Sep 26, 2022	Apr 10, 2025	Geographic Atrophy
NCT02686658	Phase 2/3	Completed	Dec 15, 2015	Apr 23, 2020	Geographic Atrophy
NCT02397954	Phase 2	Completed	Mar 12, 2015	Oct 23, 2015	Idiopathic Polypoidal Choroidal Vasculopathy
NCT00950638	Phase 1	Completed	Jul 16, 2009	Mar 24, 2011	Dry Age-Related Macular Degeneration
NCT00709527	Phase 1	Completed	Oct 16, 2008	Dec 30, 2009	Neovascular Age-Related Macular Degeneration

Competing Products

20 competing products in Geographic Atrophy

See all competitors

Product	Company	Stage	Hype Score
avacincaptad pegol	Astellas Pharma	Phase 3	40
Avacincaptad Pegol	Astellas Pharma	Phase 2/3	38
Avacincaptad pegol (ACP)	Astellas Pharma	Pre-clinical	33
Avacincaptad Pegol + Sham	Astellas Pharma	Phase 3	40
ABBV-6628 + SYFOVRE	AbbVie	Phase 1/2	39
FWY003 + Placebo	Novartis	Phase 2	42
CLG561 + LFG316 + Sham injection	Novartis	Phase 2	35
LFG316 + Sham + LFG316 Lower dose	Novartis	Phase 2	35
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
RO7669330 + Syfovre™ + Izervay™	Roche	Phase 1	36
RO7303359	Roche	Phase 1	29
SAR446597 + Sham Comparator	Sanofi	Phase 1/2	39
Pozelimab	Regeneron Pharmaceuticals	Phase 1	36
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)	Ionis Pharmaceuticals	Phase 2	24
Tinlarebant + Placebo	Belite Bio	Phase 3	41
Pegcetacoplan	Apellis Pharmaceuticals	Pre-clinical	24
APL-2 + APL-2	Apellis Pharmaceuticals	Phase 3	34
APL-2, Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	34